December 21, 2017 / 10:26 PM / a month ago

BRIEF-Celgene's regimen fails to beat chemotherapy in immune system cancer trial

Dec 21 (Reuters) - Celgene Corp:

* CELGENE AND LYSARC PROVIDE UPDATE ON PHASE III ‘RELEVANCE’ STUDY OF REVLIMID® IN COMBINATION WITH RITUXIMAB (R2) FOR THE TREATMENT OF PREVIOUSLY UNTREATED PATIENTS WITH FOLLICULAR LYMPHOMA

* CELGENE CORP - R(2 )TREATMENT ARM DID NOT ACHIEVE SUPERIORITY IN CO-PRIMARY ENDPOINTS Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below